Results 191 to 200 of about 53,350 (260)

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli   +4 more
wiley   +1 more source

Identifying Negative Biomarkers of CD4 Cytotoxic T Lymphocytes via Granzyme B Exclusion Analysis. [PDF]

open access: yesEur J Immunol
Wang B   +8 more
europepmc   +1 more source

Ezh2 Inhibits the Differentiation of Short‐Lived Effector CD8+ T Cells and Promotes T Cell‐Dependent Antitumor Immunity

open access: yesCancer Science, EarlyView.
The antitumor immune response is attenuated in T cell‐specific Ezh2 knockout mice. ABSTRACT Appropriate regulation of the differentiation balance between effector CD8+ T cells and memory CD8+ T cells is crucial for an appropriate immune response. We previously reported that the tumor suppressor menin suppresses the differentiation of CD8+ T cells into ...
Kenji Takagi   +5 more
wiley   +1 more source

Cytotoxic CD4 T Cells: Dual Agents in HIV-1 Pathogenesis and Persistence. [PDF]

open access: yesCurr HIV/AIDS Rep
Mickens KL   +4 more
europepmc   +1 more source

Hypericin Suppresses Liver Cancer Through Autophagic Degradation of AKT and Eliciting Antitumor Immune Response

open access: yesCancer Science, EarlyView.
Hypericin induces autophagic AKT degradation by promoting AKT‐HSPA5 interaction in an S473 phosphorylation‐dependent manner, suppressing HCC growth. It enhances CD8+ T cell‐mediated antitumor immunity and synergizes with anti‐PD‐L1 therapy, showing favorable safety for HCC treatment. ABSTRACT Hepatocellular carcinoma (HCC) is the most prevalent primary
Sien Ma   +12 more
wiley   +1 more source

FDX1 Depletion Activates CD8+ T Cell Antitumor Immunity by Promoting DMBT1 Secretion in Cuproptosis of Colorectal Cancer

open access: yesCancer Science, EarlyView.
Elesclomol‐induced cuproptosis potently activates both innate and adaptive antitumor immunity, especially CD8+ T cell immunity. FDX1 serves as a central regulator of CD8+ T cell functionality through DMBT1 downregulation during cuproptosis in colorectal cancer.
Jieqiong Wu   +22 more
wiley   +1 more source

Indole‐3‐Propionic Acid Drives Dendritic H3K27 Acetylation to Enhance CD8+ T Cell Immunity in Hepatocellular Carcinoma

open access: yesCancer Science, EarlyView.
The gut microbiota metabolite indole ‐ 3 ‐ propionic acid(IPA) enhanced the inhibitory effect of SCB on tumor growth in HCC mice. IPA upregulated IL‐12A expression through facilitating acetylation of H3K27 in DCs. IPA elevated IL‐12A expression in DCs to promote CD8+ T cell anti‐tumor immunity and ultimately enhances the efficacy of SCB therapy against
Rui Zhao   +7 more
wiley   +1 more source

Metabolic [¹⁸F]F-AraG PET imaging of T Cell activation: a functional complement to cell-specific immune tracers. [PDF]

open access: yesEJNMMI Res
Almutairi WM   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy